Sonoma Pharmaceuticals (SNOA) Free Cash Flow (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Free Cash Flow of -$548000.0 for Q1 2026, down 285.92% year-over-year from $294757.6 in Q1 2025, and up 32.43% quarter-over-quarter from -$811000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Free Cash Flow (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$548000.0 for Q1 2026.
- In Q1 2026, Free Cash Flow fell 285.92% year-over-year to -$548000.0; the TTM figure through Mar 2026 stood at -$4.1 million (down 2355.36% YoY), while the FY2026 annual figure was -$4.1 million, down 2355.36% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$548000.0, up from -$811000.0 in the prior quarter.
- The five-year high for Free Cash Flow was $563000.0 in Q4 2024, with the low at -$2.6 million in Q1 2023.
- The 5-year median for Free Cash Flow is -$811000.0 (2025), against an average of -$857117.6.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 150.95% in 2024, then slumped 296.65% in 2025.
- Sonoma Pharmaceuticals' Free Cash Flow stood at -$379000.0 in 2022, then plunged by 191.56% to -$1.1 million in 2023, then jumped by 150.95% to $563000.0 in 2024, then tumbled by 244.05% to -$811000.0 in 2025, then soared by 32.43% to -$548000.0 in 2026.
- Business Quant data shows SNOA's Free Cash Flow at -$548000.0 in Q1 2026, -$811000.0 in Q4 2025, and -$645000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.15 Mn | -184,359.87 | 2.58 Mn | -651,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -651,000.00 |
| Jun 30, 2026 | -651,000.00 |
| Mar 31, 2026 | -548,000.00 |
| Mar 31, 2026 | -548,000.00 |
| Dec 31, 2025 | -811,000.00 |
| Dec 31, 2025 | -811,000.00 |
| Sep 30, 2025 | -645,000.00 |
| Sep 30, 2025 | -645,000.00 |
| Jun 30, 2025 | -2.12 Mn |
| Jun 30, 2025 | -2.12 Mn |
| Mar 31, 2025 | -142,000.00 |
| Mar 31, 2025 | -142,000.00 |
| Dec 31, 2024 | 563,000.00 |
| Dec 31, 2024 | 563,000.00 |
| Sep 30, 2024 | 328,000.00 |
| Sep 30, 2024 | 328,000.00 |
| Jun 30, 2024 | -917,000.00 |
| Jun 30, 2024 | -917,000.00 |
| Mar 31, 2024 | 170,000.00 |
| Mar 31, 2024 | 170,000.00 |